Published in Drug Week, September 2nd, 2005
The company also reported that, as of July 31, 2005, it had enrolled more than 1,500 patients in a phase 3 clinical trial of its lead product candidate, Veronate.
William D. Johnston, PhD, president and chief executive officer of Inhibitex, said, "Our phase 3 clinical trial for Veronate for the prevention of hospital-associated infections in premature, very low birth weight infants continues to enroll well."
At June 30, 2005, the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.